Moomoo AI 已提取核心信息
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc. CEO & President, Kewalramani Reshma, completed a sale of 9,386 shares of common stock on February 23, 2024. The transaction was carried out at a price of $431.79 per share, resulting in a total value of approximately $4.05 million. Following the sale, Kewalramani holds 136,507 shares of Vertex Pharmaceuticals directly. The sale was executed as a means to cover the exercise price or tax liability by delivering or withholding securities, according to the transaction code description.
Vertex Pharmaceuticals Inc.首席执行官兼总裁凯瓦尔拉玛尼·雷什玛于2024年2月23日完成了9,386股普通股的出售。该交易以每股431.79美元的价格进行，总价值约为405万美元。出售后，Kewalramani直接持有Vertex Pharmicals的136,507股股份。根据交易代码的描述，此次出售是通过交付或预扣证券来支付行使价或纳税义务的一种手段。
Vertex Pharmaceuticals Inc.首席执行官兼总裁凯瓦尔拉玛尼·雷什玛于2024年2月23日完成了9,386股普通股的出售。该交易以每股431.79美元的价格进行，总价值约为405万美元。出售后，Kewalramani直接持有Vertex Pharmicals的136,507股股份。根据交易代码的描述，此次出售是通过交付或预扣证券来支付行使价或纳税义务的一种手段。
有用
没用